Stephanie Perrino

Dr. Stephanie Perrino

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
YBYasmine Benslimane
Yasmine Benslimane
KAKevin Amalfi
Kevin Amalfi
SLSara Lapin
Sara Lapin
SPStephanie Perrino
Stephanie Perrino
PBPnina Brodt
Pnina Brodt
Liver metastases (LM) remain a major cause of cancer-related death and are a major clinical challenge. LM and the female sex are predictors of a poorer response to immunotherapy but the underlying mechanisms remain unclear. We previously reported on a sexual dimorphism in the control of the tumor microenvironment (TME) of colorectal carcinoma liver metastases (CRCLM) and identified estrogen as a regulator of an immunosuppressive TME in the liver. Here we aimed to assess the effect of estrogen deprivation on the cytokine/chemokine profile associated with CRCLM, using a multiplex cytokine array and the RNAscope technology, and its effects on the innate and adaptive immune responses in the liver. We also evaluated the benefit of combining the selective estrogen-receptor degrader Fulvestrant with immune checkpoint blockade for the treatment of CRCLM. We show that estrogen depletion altered the cytokine/chemokine repertoire of the liver, decreased macrophage polarization, as reflected in reduced accumulation of tumor infiltrating M2 macrophages and increased the accumulation of CCL5+/CCR5+ CD8+ T and NKT cells in the liver TME. Similar results were obtained in a murine pancreatic ductal adenocarcinoma model. Importantly, treatment with Fulvestrant also increased the accumulation of CD8+CCL5+, CD8+CCR5+ T and NK cells in the liver TME and enhanced the therapeutic benefit of anti-PD1 immunotherapy, resulting in a significant reduction in the outgrowth of LM. Taken together, our results show that estrogen regulates immune cell recruitment to the liver and suggest that inhibition of estrogen action could potentiate the tumor-inhibitory effect of immunotherapy in hormone-independent and immunotherapy-resistant metastatic cancer. Significance: The immune microenvironment of the liver plays a major role in controlling the expansion of hepatic metastases and is regulated by estrogen. We show that treatment of tumor-bearing mice with an estrogen receptor degrader potentiated an anti-metastatic effect of immunotherapy. Our results provide mechanistic insight into clinical findings and a rationale for evaluating the efficacy of combination anti-estrogen and immunotherapy for prevention and/or treatment of hepatic metastases in female patients.

1 April 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
JTJennifer Tsui
Jennifer Tsui
SQShu Qi
Shu Qi
SPStephanie Perrino
Stephanie Perrino
MLMatthew Leibovitch
Matthew Leibovitch
PBPnina Brodt
Pnina Brodt
Triple negative breast cancer (TNBC) is associated with unfavorable prognosis and high relapse rates following chemotherapy. There is an urgent need to develop effective targeted therapy for this BC subtype. The type I insulin-like growth factor receptor (IGF-IR) was identified as a potential target for BC management. We previously reported on the production of the IGF-Trap, a soluble IGF-1R fusion protein that reduces the bioavailability of circulating IGF-1 and IGF-2 to the cognate receptor, impeding signaling. In nude mice xenotransplanted with the human TNBC MDA-MB-231 cells, we found variable responses to this inhibitor. We used this model to investigate potential resistance mechanisms to IGF-targeted therapy. We show here that prolonged exposure of MDA-MB-231 cells to the IGF-Trap in vitro selected a resistant subpopulation that proliferated unhindered in the presence of the IGF-Trap. We identified in these cells increased fibroblast growth factor receptor 1 (FGFR1) activation levels that sensitized them to the FGFR1-specific tyrosine kinase inhibitor PD166866. Treatment with this inhibitor caused cell cycle arrest in both the parental and resistant cells, markedly increasing cell death in the latter. When combined with the IGF-Trap, an increase in cell cycle arrest was observed in the resistant cells. Moreover, FGFR1 silencing increased the sensitivity of these cells to IGF-Trap treatment in vivo. Our data identify increased FGFR1 signaling as a resistance mechanism to targeted inhibition of the IGF-IR and suggest that dual IGF-1R/FGFR1 blockade may be required to overcome TNBC cell resistance to IGF-axis inhibitors.

28 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SPStephanie Perrino
Stephanie Perrino
UVUdi Vazana
Udi Vazana
OPOfer Prager
Ofer Prager
LSLior Schori
Lior Schori
GBGal Ben-Arie
Gal Ben-Arie
PBPnina Brodt
Pnina Brodt
Background: Glioblastoma multiforme is an aggressive malignancy with a dismal 5-year survival rate of 5–10%. Current therapeutic options are limited, due in part to drug exclusion by the blood–brain barrier (BBB). We have previously shown that high-amplitude repetitive transcranial magnetic stimulation (rTMS) in rats allowed the delivery across the BBB of an IGF signaling inhibitor—IGF-Trap. The objective of this study was to assess the therapeutic effect of IGF-Trap when delivered in conjunction with rTMS on the intracerebral growth of glioma. Results: We found that systemic administration of IGF-Trap without rTMS had a minimal effect on the growth of orthotopically injected glioma cells in rats and mice, compared to control animals injected with vehicle only or treated with sham rTMS. In rats treated with a combination of rTMS and IGF-Trap, we observed a growth retardation of C6 tumors for up to 14 days post-tumor cell injection, although tumors eventually progressed. In mice, tumors were detectable in all control groups by 14–17 days post-injection of glioma GL261 cells and progressed rapidly thereafter. In mice treated with rTMS prior to IGF-Trap administration, tumor growth was inhibited or delayed, although the tumors also eventually progressed. Conclusion: The results showed that rTMS could increase the anti-tumor effect of IGF-Trap during the early phases of tumor growth. Further optimization of the rTMS protocol is required to improve survival outcomes.

28 March 2025
Verified
Other
Open access
YBYasmine Benslimane
Yasmine Benslimane
KAKevin Amalfi
Kevin Amalfi
SLSara Lapin
Sara Lapin
SPStephanie Perrino
Stephanie Perrino
PBPnina Brodt
Pnina Brodt
Table S3 from Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive Microenvironment

28 March 2025
Verified
Other
Open access
YBYasmine Benslimane
Yasmine Benslimane
KAKevin Amalfi
Kevin Amalfi
SLSara Lapin
Sara Lapin
SPStephanie Perrino
Stephanie Perrino
PBPnina Brodt
Pnina Brodt
Macrophages analyses. Shown in (a) are the M1:M2 macrophages ratio analysis results using additional CD38 marker (n=3-4) and (b) TNF-alpha for M1-like macrophages characterization, and the use of the additional OVX+E2 experimental group which shows a reverse trend upon estrogen supplementation compared to the OVX group (n=3-4). Shown in (c) are the macrophages flow cytometry analysis results in FC1199 pancreatic liver metastasis model at Day 12 post-tumor injection (n=4).

28 March 2025
Verified
Other
Open access
YBYasmine Benslimane
Yasmine Benslimane
KAKevin Amalfi
Kevin Amalfi
SLSara Lapin
Sara Lapin
SPStephanie Perrino
Stephanie Perrino
PBPnina Brodt
Pnina Brodt
Lymphocytes flow cytometry analyses in FC1199 tumor model. Shown are the lymphocytes flow cytometry analysis of lymphocytes in FC1199 pancreatic liver metastasis model at Day 8 post-tumor injection in SHAM-control, OVX, and OVX + E2 mice (n=4).